Shares of Maryland-based OpGen Inc. OPGN,
43% hit active pre-market trading on Thursday after the molecular diagnostics company said that its Germany-based Curetis GmbH subsidiary had obtained the CE marking certification in the European Union for its SARS-CoV-2 test kit. Trading volume was 5.4 million shares, already more than half of the full-day average of 9.7 million shares. It uses mouth and nose pads to test people suspected of COVID-19 by their healthcare provider as well as to screen for asymptomatic individuals. “By launching this new product in Europe, we are committed to helping our distributors and customers expand the availability of SARS-CoV-2 diagnostic tests, and our own developed CE-IVD branded SARS-CoV-2 Kit with PULB expected to help increase the availability of these much-needed tests, “said Oliver Schacht, Chief Executive Officer of OpGen. The stock has risen 81.4% until Wednesday, while the S&P 500 SPX,
has received 4.5%.
.
